INTRODUCTION
============

Breast cancer (BC) is the most common cancer afflicting women and the leading cause of cancer-related deaths in this population worldwide \[[@B1]\]. Although advances in the diagnosis and treatment of BC have reduced its mortality rates, the overall prognosis of patients with distant metastasis is still unsatisfactory. Therefore, it is essential to identify new therapeutic and prognostic biomarkers of BC, which would also provide a better understanding of this malignancy at the molecular level.

Chemokine signaling is mediated by a family of G protein-coupled receptors, among which C-X-C motif chemokine receptor 4 (CXCR4) is one of the most commonly expressed on tumor cells. Müller et al.\[[@B2]\] have first documented the significant role of CXCR4 in BC metastasis, and since then, a growing body of evidence has shown that engagement of CXCR4 by its specific ligand C-X-C motif chemokine 12 (CXCL12) activates multiple intracellular pathways that contribute to metastasis and influence the clinical outcomes of various tumors \[[@B3][@B4]\].

The integrin family of cell surface adhesion molecules composed of 18 α and 8 β subunits that form at least 24 heterodimeric receptors. The β6 subunit forms only one integrin, αvβ6, which is exclusively expressed on epithelial cells. Notably, αvβ6 is expressed at high levels in several tissues during development, but in adults, it is mainly expressed during physiological tissue remodeling events, such as wound healing, and pathological events, such as carcinogenesis \[[@B5][@B6]\]. αvβ6-mediated intracellular signaling has been shown to modulate diverse processes with important roles in tumor progression, including cell proliferation, invasion, metastasis, and survival \[[@B7][@B8]\].

Recent evidence suggests that CXCR4--CXCL12 signaling may promote metastasis of colon cancer to the liver by upregulating αvβ6 expression \[[@B9]\], which prompted us to investigate the relationship between CXCR4 and αvβ6 in BC. Here, we evaluated the expression of both molecules, alone and in combination, in BC tissues and determined their prognostic significance, with the goal of providing new insights into our understanding of the molecular mechanisms underlying BC development and progression.

METHODS
=======

Patients and clinical samples
-----------------------------

This study enrolled 111 women who were pathologically diagnosed with invasive ductal carcinoma at the First Affiliated Hospital of China Medical University between 2008 and 2009. Inclusion criteria were: 1) curative surgery and pathologically confirmed infiltrative ductal carcinoma; 2) no evidence of distant metastasis in preoperative examination and no preoperative anticancer treatment; 3) availability of complete medical information and follow-up data; and 4) availability of paraffin-embedded resected tissues. The median age at diagnosis was 52 years (range, 29--82). According to the clinical tumor-node-metastasis classification set by the 6th edition of the American Joint Committee on Cancer staging system, 44 patients had stage I disease, 50 had stage II, and 17 had stage III. This retrospective study was approved by the Ethics Committee of the First Affiliated Hospital of China Medical University (Institutional Review Board approval No. AF-SOP-07-1.1-01); the requirement for informed patient consent was waived.

Immunohistochemistry
--------------------

Formalin-fixed, paraffin-embedded BC tissues and adjacent normal tissues were cut into 4-μm-thick sections, and immunohistochemical staining was performed with the streptavidin-peroxidase method. In brief, sections were heated at 65°C for 2 hours, dewaxed in xylene, rehydrated in a graded alcohol series, and washed with phosphate-buffered saline (PBS). The sections were then subjected to high-pressure antigen retrieval for 2 minutes in citrate buffer (pH 6.0), and endogenous peroxidase was blocked with hydrogen peroxide. The sections were incubated with primary antibodies against CXCR4 (ab1670, 1:200 dilution; Abcam, Cambridge, UK) or integrin αvβ6 (bs-5791R, 1: 400; Bioss Inc., Beijing, China) at 4°C overnight. As negative controls, sections were incubated with PBS instead of the primary antibodies. The sections were then incubated with secondary antibodies (Maixin-Bio, Fuzhou, China) at 37°C for 30 minutes, and antibody binding was visualized by addition of 3,3-diaminobenzidine.

Evaluation of immunohistochemical staining
------------------------------------------

All sections were randomly and blindly evaluated by 2 pathologists. Staining of the cell membranes and cytoplasm was considered positive expression. Staining was evaluated using a semi-quantitative scoring system \[[@B10]\] that takes into account the intensity and extent of staining. Intensity was scored as: 0, no staining; 1, weak; 2, moderate; and 3, high staining. The extent of staining (percentage of stained tumor cells) was scored as: 1, 1%--25%; 2, 26%--50%; 3, 51%--75%; and 4, 76%--100%. The final immunohistochemistry score (IHS) was the product of the intensity score and the extent of staining score and ranged from 0 to 12. For correlation analysis, patients were assigned to either a high (IHS ≥ 4) or low (IHS \< 4) αvβ6 or CXCR4 expression group.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS 20.0 software (IBM, Armonk, USA). Graphical representations were performed using GraphPad Prism 7.0 software (GraphPad Software, San Diego, USA). The relationships between CXCR4, αvβ6, and clinicopathological factors were analyzed by the χ^2^ test. Spearman\'s rank correlation analysis and the Mann--Whitney test were applied to evaluate the relationship between CXCR4 and αvβ6 expression. The Kaplan--Meier method was used to calculate overall survival (OS) and disease-free survival (DFS), and differences were evaluated using the log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards regression model. All tests were 2-sided, and a *p-*value of \< 0.05 was considered statistically significant.

RESULTS
=======

CXCR4 and αvβ6 expression in BC tissues
---------------------------------------

The expression of CXCR4 and αvβ6 in 111 BC samples and 40 adjacent normal tissues was analyzed by immunohistochemical staining. Both CXCR4 and αvβ6 were mainly located in the cell membranes and cytoplasm of BC cells ([Figure 1](#F1){ref-type="fig"}). CXCR4 was overexpressed in 58 (52.3%) of the BC tissues examined, and αvβ6 was overexpressed in 43 (38.7%) BC tissues. Notably, 40 (36.0%) of BC tissues overexpressed both CXCR4 and αvβ6. All 40 samples of adjacent normal tissues were negative for both proteins ([Table 1](#T1){ref-type="table"}).

![Immunohistochemical staining of CXCR4 and αvβ6 in BC and normal breast tissue (×200). (A) CXCR4 positive staining in BC. (B) CXCR4 negative staining in BC. (C) CXCR4 negative staining in normal breast tissue. (D) Integrin αvβ6 positive staining in BC. (E) Integrin αvβ6 negative staining in BC. (F) Integrin αvβ6 negative staining in normal breast tissue.\
BC = breast cancer; CXCR4 = C-X-C motif chemokine receptor 4.](jbc-23-171-g001){#F1}

###### Clinicopathological characteristics of patient samples and expression of CXCR4 and integrin αvβ6 in breast cancer

![](jbc-23-171-i001)

  Characteristics                                No. of cases   
  ---------------------------------------------- -------------- -----------
  Age (yr)                                                      
                                                 \< 60          91 (82.0)
                                                 ≥ 60           20 (18.0)
  Tumor size (cm)                                               
                                                 ≤ 2            44 (39.6)
                                                 \> 2           12 (10.8)
  Lymph node metastasis                                         
                                                 Yes            47 (42.3)
                                                 No             64 (57.7)
  Histological grade                                            
                                                 1              31 (27.9)
                                                 2 + 3          80 (72.1)
  ER expression                                                 
                                                 Negative       38 (34.2)
                                                 Positive       73 (65.8)
  PR expression                                                 
                                                 Negative       44 (39.6)
                                                 Positive       67 (60.4)
  HER-2 amplification                                           
                                                 Yes            25 (22.5)
                                                 No             86 (77.5)
  CXCR4 expression                                              
                                                 Low            53 (47.7)
                                                 High           58 (52.3)
  Integrin αvβ6 expression                                      
                                                 Low            68 (61.3)
                                                 High           43 (38.7)
  Co-overexpression of CXCR4 and integrin αvβ6                  
                                                 Yes            40 (36.0)
                                                 No             71 (64.0)

Values are presented as number (%).

ER = estrogen receptor; PR = progesterone receptor; HER-2 = human epidermal growth factor receptor 2; CXCR4 = C-X-C motif chemokine receptor 4.

Correlations between CXCR4 and αvβ6 expression in BC tissue and clinicopathological characteristics
---------------------------------------------------------------------------------------------------

As shown in [Table 2](#T2){ref-type="table"}, CXCR4 overexpression was significantly associated with lymph node metastasis (*p* = 0.013), whereas αvβ6 overexpression correlated with tumor size (*p* = 0.044) and lymph node metastasis (*p* = 0.022). Co-overexpression of both CXCR4 and αvβ6 was significantly associated with larger tumor size (*p* = 0.018) and lymph node metastasis (*p* = 0.015). However, there were no correlations between overexpression of either protein and age, histological grade, estrogen receptor expression, progesterone receptor expression, or human epidermal growth factor receptor 2 (HER-2) status ([Table 2](#T2){ref-type="table"}).

###### Relationships among the expression of CXCR4, integrin αvβ6 and clinicopathological factors in breast cancer

![](jbc-23-171-i002)

  Characteristics         No. of cases   CXCR4 expression   *p*-value   Integrin αvβ6 expression   *p*-value   Co-overexpression of CXCR4 and integrin αvβ6   *p*-value           
  ----------------------- -------------- ------------------ ----------- -------------------------- ----------- ---------------------------------------------- ----------- ---- -- -------
  Age (yr)                                                              0.079                                                                                 0.254               0.151
                          \< 60          91                 47          44                         58          33                                             30          61      
                          ≥ 60           20                 6           14                         10          10                                             10          10      
  Tumor size (cm)                                                       0.121                                                                                 0.044               0.018
                          ≤ 2            44                 25          19                         32          12                                             10          34      
                          \> 2           67                 28          39                         36          31                                             30          37      
  Lymph node metastasis                                                 0.013                                                                                 0.022               0.015
                          Yes            47                 16          31                         23          24                                             23          24      
                          No             64                 37          27                         45          19                                             17          47      
  Histological grade                                                    0.176                                                                                 0.082               0.066
                          1              31                 18          13                         23          8                                              7           24      
                          2 + 3          80                 35          45                         45          35                                             33          47      
  ER expression                                                         0.954                                                                                 0.264               0.480
                          Low            38                 18          20                         26          12                                             12          26      
                          High           73                 35          38                         42          31                                             28          45      
  PR expression                                                         0.700                                                                                 0.677               0.729
                          Low            44                 22          22                         28          16                                             15          29      
                          High           67                 31          36                         40          27                                             25          42      
  HER-2 amplification                                                   0.073                                                                                 0.540               0.346
                          Yes            25                 8           17                         14          11                                             11          14      
                          No             86                 45          41                         54          32                                             29          57      

CXCR4 = C-X-C motif chemokine receptor 4; ER = estrogen receptor; PR = progesterone receptor; HER-2 = human epidermal growth factor receptor 2.

Correlation between CXCR4 and αvβ6 expression in BC
---------------------------------------------------

CXCR4 and αvβ6 expression in BC were significantly positively correlated; thus, of the 58 BC tissues overexpressing CXCR4, 40 (69.0%) also overexpressed αvβ6 (Spearman rank correlation *r* = 0.649, *p=*0.001) ([Table 3](#T3){ref-type="table"}). After assigning the 111 patients into low (\< 4 IHS) or high (≥ 4 IHS) expression of CXCR4 groups, αvβ6 expression, based on the IHS score, was found to be significantly higher in the CXCR4-high group than in the CXCR4-low group (*p* \< 0.001, [Figure 2](#F2){ref-type="fig"}).

###### Correlation between CXCR4 and integrin αvβ6 in patients with breast cancer

![](jbc-23-171-i003)

  Integrin αvβ6 expression   CXCR4 expression   Total       
  -------------------------- ------------------ ----------- -----
  Low                        50 (94.3)          18 (31.0)   68
  High                       3 (5.7)            40 (69.0)   43
  Total                      53                 58          111

Values are presented as number (%).

CXCR4 = C-X-C motif chemokine receptor 4.

![Box-and-whisker graph demonstrated that IHS of integrin αvβ6 in CXCR4-high group was significantly higher than CXCR4-low group.\
IHS = immunohistochemistry score; CXCR4 = C-X-C motif chemokine receptor 4.\
^\*^*p* \<  0.001.](jbc-23-171-g002){#F2}

Prognostic significance of CXCR4 and αvβ6 expression in BC
----------------------------------------------------------

The 111 patients were followed up for a median duration of 114 months (range, 5--127 months). During the follow-up period, 33.3% (37/111) of patients experienced distant metastasis. Associations between CXCR4 and αvβ6 expression and patient outcome were evaluated using the Kaplan--Meier method and log-rank test. As shown in [Figure 3](#F3){ref-type="fig"}, the OS and DFS were shorter for patients with high CXCR4 expression compared with low expression (*p* \< 0.001 for OS and DFS) and for patients with high αvβ6 expression compared with low expression (*p* \< 0.001 for OS, *p* = 0.005 for DFS). Moreover, we divided the patients into 3 groups based on CXCR4 and αvβ6 expression: group 1, with CXCR4 (high) and αvβ6 (high) (n = 40); group 2, CXCR4 (high) and αvβ6 (low)/CXCR4 (low) and αvβ6 (high) (n = 21); and group 3, with CXCR4 (low) and αvβ6 (low) (n = 50). Importantly, the 40 patients co-overexpressing CXCR4 and αvβ6 had a significantly poorer prognosis than the other groups (*p* = 0.009 for OS, *p* = 0.019 for DFS) ([Figure 3C and F](#F3){ref-type="fig"}).

![Kaplan--Meier curves for OS and DFS in patients with breast cancer (111 cases) according to CXCR4 and integrin αvβ6 expression. *p*-values determined using log-rank test. (A, D) Kaplan--Meier curves for OS and DFS according to CXCR4-expression status (n = 111). (B, E) Kaplan--Meier curves for OS and DFS according to integrin αvβ6 expression status (n = 111). (C, F) Kaplan--Meier curves for OS and DFS according to combined expression of CXCR4 and integrin αvβ6 status (n = 111).\
OS = overall survival; DFS = disease-free survival; CXCR4 = C-X-C motif chemokine receptor 4.](jbc-23-171-g003){#F3}

Next, we assessed the prognostic value of CXCR4 and αvβ6 expression and other clinicopathological characteristics using a Cox proportional hazards model. Univariate analysis revealed that lymph node metastasis (*p* \< 0.001 for OS and DFS), histological grade (*p* = 0.007 for OS, *p* = 0.009 for DFS), CXCR4 overexpression (*p* = 0.001 for OS, *p* = 0.002 for DFS), αvβ6 overexpression (*p* = 0.012 for OS, *p* = 0.007 for DFS), and CXCR4 and αvβ6 co-overexpression (*p* = 0.003 for OS, *p* = 0.006 for DFS) predicted a poorer prognosis. Tumor size correlated only with shorter OS (*p* = 0.035) ([Table 4](#T4){ref-type="table"}). In multivariate analysis, only lymph node metastasis (*p* = 0.002 for OS, *p* = 0.005 for DFS) and CXCR4 and αvβ6 co-overexpression (*p* = 0.043 for OS) remained independent prognostic factors for BC patients ([Table 5](#T5){ref-type="table"}).

###### Univariate analysis of OS and DFS in breast cancer

![](jbc-23-171-i004)

  Variable   Univariable analysis                                                       
  ---------- -------------------------------------------------- ------- --------------- ----------
  OS                                                                                    
             Age (\< 60 vs. ≥ 60)                               1.242   0.542--2.844    0.608
             Tumor size (\> 2 cm vs. ≤ 2 cm)                    2.259   1.058--4.823    0.035
             Lymph node metastasis (yes vs. no)                 5.126   2.392--10.987   \< 0.001
             Historical grade (2 & 3 vs. 1)                     5.109   1.536--16.696   0.007
             Surgery (MRD vs. other approaches^\*^)             0.616   0.255--1.490    0.282
             Chemotherapy (yes vs. no)                          3.357   0.459--24.569   0.233
             Endocrine therapy (yes vs. no)                     0.874   0.440--1.735    0.700
             Radiation therapy (yes vs. no)                     1.074   0.536--2.044    0.849
             CXCR4 expression (high vs. low)                    3.891   1.757--8.613    0.001
             αvβ6 expression (high vs. low)                     2.365   1.208--4.630    0.012
             Co-overexpression of CXCR4 and αvβ6 (yes vs. no)   2.729   1.394--5.342    0.003
  DFS                                                                                   
             Age (\< 60 vs. ≥ 60)                               1.141   0.500--2.602    0.754
             Tumor size (\> 2 cm vs. ≤ 2cm)                     1.792   0.885--3.627    0.105
             Lymph node metastasis (yes vs. no)                 4.242   2.087--8.624    \< 0.001
             Historical grade (2 & 3 vs. 1)                     3.984   1.410--11.258   0.009
             Surgery (MRD vs. other approaches)                 0.710   0.296--1.715    0.444
             Chemotherapy (yes vs. no)                          3.837   0.525--28.025   0.185
             Endocrine therapy (yes vs. no)                     0.985   0.487--1.885    0.900
             Radiation therapy (yes vs. no)                     1.150   0.600--2.206    0.673
             CXCR4 expression (high vs. low)                    3.348   1.578--7.104    0.002
             αvβ6 expression (high vs. low)                     2.461   1.283--4.723    0.007
             Co-overexpression of CXCR4 and αvβ6 (yes vs. no)   2.495   1.305--4.771    0.006

OS = overall survival; DFS = disease-free survival; CI = confidence interval; HR = hazard ratio; MRD = modified radical mastectomy; CXCR4 = C-X-C motif chemokine receptor 4.

^\*^Other approaches were breast-conserving and total mastectomy plus sentinel lymph node biopsy.

###### Multivariate analysis of OS and DFS in breast cancer

![](jbc-23-171-i005)

  Variable   Multivariable analysis                                                    
  ---------- -------------------------------------------------- ------- -------------- -------
  OS                                                                                   
             Age (\< 60 vs. ≥ 60)                               \-      \-             \-
             Tumor size (\> 2 cm vs. ≤ 2 cm)                    \-      \-             \-
             Lymph node metastasis (yes vs. no)                 3.491   1.555--7.837   0.002
             Historical grade (2 & 3 vs. 1)                     \-      \-             \-
             Co-overexpression of CXCR4 and αvβ6 (yes vs. no)   2.030   1.023--4.029   0.043
  DFS                                                                                  
             Age (\< 60 vs. ≥ 60)                               \-      \-             \-
             Tumor size (\> 2 cm vs. ≤ 2 cm)                    \-      \-             \-
             Lymph node metastasis (yes vs. no)                 3.007   1.405--6.437   0.005
             Historical grade (2 & 3 vs. 1)                     \-      \-             \-
             Co-overexpression of CXCR4 and αvβ6 (yes vs. no)   \-      \-             \-

OS = overall survival; DFS = disease-free survival; CI = confidence interval; HR = hazard ratio; CXCR4 = C-X-C motif chemokine receptor 4.

DISCUSSION
==========

The incidence of BC has been slowly increasing and it poses a major threat to women\'s health worldwide. A better understanding of the molecular mechanisms underlying this malignancy would contribute to earlier diagnosis and better treatment options. In the present study, we found that both CXCR4 and αvβ6 were overexpressed in BC compared with adjacent normal breast tissues, and that overexpression of either molecule correlated significantly with clinicopathological factors and patient survival. Moreover, we detected a positive correlation between the expression of CXCR4 and the expression of αvβ6 in BC tissue.

Binding of the chemokine CXCL12 to CXCR4 plays a well-established role in promoting tumor cell proliferation, invasion, and angiogenesis \[[@B11][@B12]\]. Accordingly, the CXCR4--CXCL12 signaling axis has been shown to contribute to the metastasis and clinical outcome of many different types of cancers \[[@B13][@B14]\]. Here, we found that CXCR4 overexpression in BC tissues was associated with lymph node metastasis, and shorter OS and DFS. These results are in agreement with previous studies in BC demonstrating that CXCR4 overexpression plays a prominent role in metastasis and correlates with unfavorable prognosis \[[@B15][@B16]\].

αvβ6 is a unique member of the integrin family in that its expression is restricted to epithelial cells and is usually expressed only during embryogenesis and under select conditions in adults; namely, during wound healing and in epithelial tumors \[[@B5]\]. αvβ6 has been shown to modulate cell invasion, inhibit apoptosis, regulate the expression of matrix metalloproteases (MMPs), and induce the production of transforming growth factor (TGF) β1 \[[@B17][@B18]\]. Overexpression of αvβ6 has also been associated with aggressive tumor behavior and poor survival in many types of cancer \[[@B7][@B19][@B20]\]. Upregulation of αvβ6 in myoepithelial cells in ductal carcinoma *in situ* not only induces its tumor-promoting functions via TGF-β and MMP9 signaling \[[@B21]\], but also induces its loss of response to a stiffening microenvironment, which lead to increase in tissue rigidity \[[@B22]\]. In turn, these changes result in a switch in myoepithelial cells from tumor suppressors to tumor promoters \[[@B23]\]. In support of these results, we found that αvβ6 overexpression in BC was significantly associated with tumor size, lymph node metastasis, and poorer survival. Another study has found that αvβ6 is upregulated in HER-2 overexpressing tumors and is an independent prognostic marker in HER-2 positive BC \[[@B24]\]. However, we did not detect a relationship between αvβ6 overexpression and HER-2 status or expression of estrogen or progesterone receptors. These discrepancies may be due to inter-study differences in the racial composition of the patient population, selection criteria, sample size, tissue preservation methods, staining antibodies, and data extraction methods.

Multiple factors contribute to the aggressive behavior of tumors. CXCR4-overexpressing tumor cells exhibit directional migration along a CXCL12 gradient in organs rich in this chemokine, such as lymph node, bone, lung, and liver \[[@B2]\]. However, other studies have found that CXCR4 contributes to tumor growth not through a direct role in adhesion and migration but rather through CXCL12-triggered signaling and modulation of cell adhesion through integrin receptors \[[@B25][@B26]\]. Wang et al. \[[@B9]\] have found that expression of CXCR4 and αvβ6 was strongly associated with colorectal cancer (CRC) metastasis to the liver. They showed that CXCR4--CXCL12 interactions upregulated the expression of αvβ6 via the extracellular signal-regulated kinase--Est-1 pathway, and induced the directional migration of CRC cells to the liver via αvβ6. Similarly, CXCR4--CXCL12 induces ovarian cancer cell invasion through αvβ6-mediated p38 mitogen-activated protein kinase and phosphoinositide 3-kinase/protein kinase B signaling and urokinase expression \[[@B27]\]. However, little was known in the past about the relationship between CXCR4 and αvβ6 in BC. Here, we found that co-overexpression of CXCR4 and αvβ6 in tumor tissue was associated with larger tumor size, lymph node metastasis, and shorter DFS and OS. Moreover, co-overexpression of CXCR4 and αvβ6 was an independent prognostic factor for unfavorable OS in BC. We also detected a positive correlation between CXCR4 and αvβ6 expression in BC tissues; therefore, we hypothesize that the 2 proteins may functionally interact. However, our study sample was small, and further investigation is warranted of the co-expression and possible functional associations between CXCR4 and αvβ6 in cell lines and animal models. Despite this limitation, the results of our study suggest the possibility of crosstalk between CXCR4 and αvβ6 in BC.

Given that CXCR4 and αvβ6 play important roles in the malignant progression of multiple cancers, numerous studies have investigated the anticancer effects of therapy targeted to CXCR4 or αvβ6. In a phase I trial, balixafortide, a potent, selective CXCR4 antagonist, in combination with eribulin showed encouraging signs of anticancer activity in women with HER-2 negative, CXCR4-positive metastatic BC \[[@B28]\]. Similarly, 264RAD, a potent human monoclonal antibody against αvβ6, has shown promise in significantly reducing tumor growth and metastasis of BC \[[@B29]\]. 264RAD can also enhance the effect of trastuzumab, thereby offering a potential alternative approach to the treatment of high-risk and trastuzumab-resistant BC patients \[[@B30]\]. Based on these results, we hypothesize that patients with CXCR4 and αvβ6 co-overexpressing tumors might benefit from co-targeted treatment. This possibility will be tested in our future work.

In summary, we found that CXCR4 and αvβ6 are highly expressed in BC, and that their overexpression correlates with several clinicopathological characteristics and clinical outcomes in BC patients. Most importantly, CXCR4 expression and αvβ6 expression were positively correlated, and patients co-overexpressing the 2 proteins showed a poorer prognosis. These findings suggest not only that a functional interaction between the 2 proteins may play an important role in the development of BC, but also that co-targeting of CXCR4 and αvβ6 may represent a new strategy for the prevention and treatment of BC.
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